Clinical Trial: NCT04930536
Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma
Status:
COMPLETEDPhase:
Phase 4| Lead Sponsor: | AstraZeneca |
| Information Provided By: | AstraZeneca |
| Last Update Posted: | 2024-11-22 |
Study Overview
Brief Summary
This study is plan to assess the safety and efficacy of Acalabrutinib in Indian patients with chronic lymphocytic leukaemia (CLL) and relapsed and refractory mantle cell lymphoma (MCL)
Official Title
A Prospective, Multi-centre, Phase IV Clinical Trial to Assess the Safety and Efficacy of Acalabrutinib Capsules in Indian Adult Patients With Chronic Lymphocytic Leukaemia and Relapsed and Refractory Mantle Cell Lymphoma.
Conditions
Chronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell Lymphoma
Intervention / Treatment
- Drug: Acalabrutinib capsule
Other Study ID Numbers
- D8220C00022
Start Date (Actual)
2021-07-14
Primary Completion Date (Actual)
2023-05-02
Study Completion Date (Actual)
2023-05-02
Enrollment (Actual)
103
Study Type
Interventional
Phase
Phase 4
| Lead Sponsor: | AstraZeneca |
| Information Provided By: | AstraZeneca |
| Last Update Posted: | 2024-11-22 |
Study Overview
Brief Summary
This study is plan to assess the safety and efficacy of Acalabrutinib in Indian patients with chronic lymphocytic leukaemia (CLL) and relapsed and refractory mantle cell lymphoma (MCL)
Official Title
A Prospective, Multi-centre, Phase IV Clinical Trial to Assess the Safety and Efficacy of Acalabrutinib Capsules in Indian Adult Patients With Chronic Lymphocytic Leukaemia and Relapsed and Refractory Mantle Cell Lymphoma.
Conditions
Chronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell Lymphoma
Intervention / Treatment
- Drug: Acalabrutinib capsule
Other Study ID Numbers
- D8220C00022
Start Date (Actual)
2021-07-14
Primary Completion Date (Actual)
2023-05-02
Study Completion Date (Actual)
2023-05-02
Enrollment (Actual)
103
Study Type
Interventional
Phase
Phase 4